Hikma Pharmaceuticals

TICKER: HIK     EXCHANGE: LSE

Hikma conducts its business in countries with very diverse demographic, geographic, political and socio-economic profiles, healthcare structures and needs. They range from the young and fast-growing Middle East and North Africa (MENA) region to mature markets like the US and Europe. It operates three well-diversified divisions: branded generics (sold in the MENA region), injectables (MENA, US and Europe) and generics (US). 

LATEST REPORTS

 
Good for patients, good for shareholders
Published: Sep 06 2012

Hikma conducts its business in countries with very diverse demographic, geographic, political and socio-economic profiles. It operates three well-diversified divisions: branded generics (sold in the MENA region), injectables (MENA, US and Europe) and generics (US). 
Further substantial growth shown at the half year stage: a 34.8% increase in net sales to US$532.3m and a 22% increase in net profits to US$40.4m. It appears that the Group is on track to deliver 20% growth in FY2012, as per management guidance.
Ongoing focus on R&D and their continuing flow of drug approvals / launches will to continue to support strong organic growth, giving further up-side potential to this share; the nature and scale of the next deal will influence growth rate and expectations

ARCHIVE

Foreign buyers gorging on UK stocks

Document can be downloaded here: UK plc ‘going for a song’

Being a shareholder in a company that receives a juicy takeover offer is a marvellous feeling. Something that many fortunate investors have experienced over the past 3 years. Thanks to a spate of M&A bids by deep pocketed overseas buyers – partly triggered by the June 2016 Brexit result, which sent the £ tumbling and adversely affected the FTSE.

Consequently today, given this trend is unlikely to end anytime soon, we’ve highlighted 30 possible acquisition ideas in the attached research paper. Spilt equally between large and smallcap stocks – covering a broad selection of industries.

What’s more we believe most of these businesses are underpinned by strong fundamentals and substantial upside in the event of predatory interest.

According to Factset Mergerstat/BVR, the average bid premium paid for such deals between 2004-14 was 30% – with the figure trending upwards since the global financial crisis.

Happy investing. Published 27th August 2019